CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年9月7日～2025年9月13日の間に収集した論文情報を追加しました。

  1. Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System.

  抗凝固薬＋抗血小板薬で出血増、特にRIV＋ASA高リスク

  対象DB：FAERS

  2. No disproportionate reporting of inflammatory arthritis following COVID-19 vaccination: a pharmacovigilance study using VAERS data.

  COVIDワクチン後の炎症性関節炎に過報なし

  対象DB：FAERS,VAERS

  3. Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data.

  ドセタキセルAEをFAERSで解析、新規所見示唆

  対象DB：FAERS

  4. Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.

  抗癌薬でSJS/TEN、65歳超と女性高リスク

  対象DB：FAERS

  5. Fracture Risk Associated With Dimethyl Fumarate Treatment in Multiple Sclerosis Patients: Population Heterogeneity and Temporal Patterns.

  DMFで骨折AE増、性年齢でリスク差異示唆

  対象DB：FAERS

  6. Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database.

  肺炎球菌ワクチンのAEをVAERSで網羅解析

  対象DB：FAERS,VAERS

  7. An application of studying FAERS data to Enhance Drug Safety and Treatment Outcomes in Rare Diseases.

  希少疾患薬のAEをFAERSで網羅整理

  対象DB：FAERS

  8. Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and vigiaccess databases.

  抗血小板薬で中枢血腫リスク高示唆

  対象DB：FAERS

  9. Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports.

  BPと多剤で強シグナル、特にVIL高リスク

  対象DB：FAERS

  10. Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis.

  眼瞼炎等と全身薬の関連をFAERSで特定

  対象DB：FAERS

  11. Overall safety evaluation of the risk signals of sacubitril/valsartan: A postmarketing pharmacoepidemiology study from 2015 to 2024.

  サクビトリル/バルサルタンで新規AE多数検出

  対象DB：FAERS

  12. Drug-associated postpartum hemorrhage: a comprehensive disproportionality analysis based on the FAERS database.

  PPH関連薬32種特定、長期リスク示唆

  対象DB：FAERS

  13. Real-world pharmacovigilance assessment of drug-induced male hypogonadism risks: An analysis of FDA adverse drug event data.

  男性低ゴナドー多数服用でシグナル検出

  対象DB：FAERS

  14. Drug-induced vitiligo: a real-world pharmacovigilance analysis of the FAERS database.

  白斑誘発薬多数特定、ラベル未記載多い

  対象DB：FAERS

  15. A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel.

  ゲフィチニブ/ドセの新規AEシグナル多数提示

  対象DB：FAERS

  16. Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS).

  オルメサルタンで腸症・大腸炎関連増加示唆

  対象DB：FAERS

  17. Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan.

  日本JADERでTD/EPSはFGAで高く、SGAも非使用より高リスク

  対象DB：JADER

  18. Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.

  COVID-19治療薬のCVAEは薬剤差あり、継続監視必要

  対象DB：VigiBase

  19. Socioeconomic disparities in colorectal cancer oncologic emergencies: a nationwide multilevel analysis in Japan.

  貧困地域でCRC救急発症が多く男性就労世代で顕著

  対象DB：DPC

  20. Temporal trends in acute care costs of hip fracture treatment from 2011 to 2021 in Japan.

  大腿骨骨折急性期費用、近年再上昇し日額は一貫増加

  対象DB：DPC

  21. Association between transitional care in acute care hospitals and ambulatory care sensitive condition-related readmission.

  トランジショナルケアでACSC再入院低下、効果は早期に最大

  対象DB：DPC

  22. Adjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.

  CKD患者は補助化学療法実施率低下

  対象DB：DPC

  23. Nationwide Survey of Pulmonary Physical Rehabilitation for Neonatal Respiratory Distress Syndrome in Very-Low-Birth-Weight Infants in Japan.

  VLBWI-RDSで肺理学療法実施率4.1%、平均開始30日後

  対象DB：DPC

  24. Timing of surgery and outcomes in patients with congenital pulmonary airway malformation: a national inpatient database study.

  CPAM手術時期で転帰差少、術前肺炎で麻酔延長

  対象DB：DPC

  25. Clinical characteristics and in-hospital mortality of chronic myeloid leukemia patients with ischemic heart disease: insights from the JROAD-DPC registry.

  CMLは危険因子少なくIHD入院も死亡率同等

  対象DB：DPC

  26. The efficacy of thoracic duct ligation for post-esophagectomy chylothorax in esophageal cancer: a nationwide inpatient cohort study.

  食道切除後乳び胸はTTDLがTDEより成績良好

  対象DB：DPC

  27. Thromboembolic risks after knee arthroplasty in patients with severe obesity: A large-scale analysis using Japanese medical claims data.

  肥満BMI35以上と同時両側手術でVTE増加示唆

  対象DB：DPC

  28. Retrospective claims analysis of the epidemiology and economic burden of diagnosed congenital cytomegalovirus in Japan.

  先天CMV乳児は医療利用・費用大幅増負担大

  対象DB：JMDC

  29. Short- and Long-Term Outcomes of Open, Laparoscopic, and Robot-Assisted Surgery for Rectal Cancer.

  ロボ支援直腸切除は合併症低く、生存率最良

  対象DB：MDV

  30. Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.

  アロプリ重篤皮膚症100日リスク予測モデル外部検証済

  対象DB：CPRD

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み